“Sublingual buprenorphine is associated with shorter duration of treatment than oral morphine for infants with neonatal abstinence syndrome, according to a study published online May 4 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Pediatric Academic Societies, held from May 6 to 9 in San Francisco.
The researchers found that, compared with morphine, buprenorphine correlated with significantly shorter median duration of treatment (15 versus 28 days) and median length of hospital stay (21 versus 33 days) (both P < 0.001). Adjunctive phenobarbital was administered to 15 and 23 percent of infants in the buprenorphine and morphine groups, respectively (P = 0.36). Similar rates of adverse events were seen in the groups.”
Source: EMPR.com – May 5, 2017